Straits Times Index
3,291.44 -1.25 (-0.04%) Nikkei
38,216.84 -57.21 (-0.15%) Hang Seng
18,190.77 +427.74 (+2.41%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,534.64 -2,320.77 (-3.88%) CMC Crypto 200
1,259.76 -10.99 (-0.86%)
LLY Jun 2024 640.000 call
| Previous close | 141.82 |
| Open | 141.82 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 640.00 |
| Expiry date | 2024-06-21 |
| Day's range | 141.82 - 141.82 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo Finance3 stocks with the biggest gains took April's biggest losses
The stock market's very rough April saw some of the biggest gainers of the first three months take some of the biggest dings to their market caps. And at the same time, some of the sectors that struggled in Q1 saw a similar reversal of fortune in April.
- Reuters
UPDATE 2-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The small raise to the outlook and forecast-beating results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market, which analysts have estimated could be worth as much as $100 billion by the end of the decade. Novo's growth on the back of the phenomenal success of Wegovy has nonetheless been held back by its ability to meet runaway demand for the weekly injection.
ReutersNovo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The small raise to the outlook and forecast-beating results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market, which analysts have estimated could be worth as much as $100 billion by the end of the decade. Novo's growth on the back of the phenomenal success of Wegovy has nonetheless been held back by its ability to meet runaway demand for the weekly injection.
